32.96EUR-3.17%Mkt Cap: 1.67B EURP/E: —Last update: 2026-06-01
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.67B EUR
Enterprise Value1.69B EUR
Revenue (TTM)32.59M EUR
Gross Profit32.59M EUR
Net Income (TTM)-23.96M EUR
Revenue/Share0.6820 EUR
Last Price32.96 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees100
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-143.33
PEG—
EV/EBITDA-161.09
EV/Revenue51.84
P/S52.97
P/B-19.50
EPS (TTM)-0.50
EPS (Forward)-0.24
52W Range
3.75567% of range47.66
52W High47.66 EUR
52W Low3.755 EUR
Profitability
Gross Margin100.00%
Oper. Margin-196.42%
EBITDA Margin-32.18%
Profit Margin-80.83%
ROE28.36%
ROA-35.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.42M EUR
CapEx (TTM)546.00K EUR
FCF Margin-24.22%
FCF Yield-0.47%
Net Debt42.57M EUR
Net Debt/EBITDA-4.06
Balance Sheet
Debt/Equity-1.13
Current Ratio1.09
Quick Ratio1.05
Book Value/Sh-1.7460 EUR
Cash/Share1.090 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)46.00 EUR
Target Range31.00 EUR – 60.00 EUR
# Analysts5
Ownership
Shares Out.50.71M
Float31.07M
Insiders15.55%
Institutions35.64%
Technical
SMA 5031.00 (+6.3%)
SMA 20021.21 (+55.4%)
Beta0.58
S&P 52W Chg27.94%
Avg Vol (30d)279.97K
Avg Vol (10d)317.82K
Technical Indicators
RSI (14)48.3
MACD1.0780
MACD Signal2.0952
MACD Hist.-1.0172
BB Upper46.90 EUR
BB Middle37.07 EUR
BB Lower27.24 EUR
BB Width53.03%
ATR (14)3.144 EUR
Vol Ratio (20d)0.53x